The device was not returned for evaluation.A review of the lot history record and complaint history of the reported lot could not be conducted because the part and lot number were not provided.The reported patient effects of myocardial infarction, thrombosis, ischemia and dissection, as listed in the bioresorbable vascular scaffold (bvs) system, absorb, instructions for use are known adverse events associated with the use of a coronary scaffold in native coronary arteries.Based on the information reviewed, a conclusive cause for the reported difficulties and patient effects could not be determined.There is no indication of a product quality issue with respect to manufacture, design or labeling.The absorb device is currently not commercially available in the u.S.; however, it is similar to a device sold in the us.The xience device referenced is being filed under a separate medwatch report#.The udi is unknown because the part and lot #s were not provided.Literature title: bioresorbable vascular scaffolds versus drug-eluting stents for diffuse long coronary narrowings.
|
It was reported through a research article identifying unk absorb that may be related to the following: delivery failure, dissection, myocardial infarction, thrombosis, ischemia, and revascularization.Additionally, the article identified unk xience that may be related to the following: delivery failure, death, myocardial infraction, thrombosis, ischemia, and revascularization.Specific patient information is documented as unknown.Details are listed in the article, titled: bioresorbable vascular scaffolds versus drug-eluting stents for diffuse long coronary narrowings.
|